|ATNM -- USA Stock|| |
USD 0.74 0.0083 1.14%
Dr. Nitya G. Ray Ph.D. is Executive Vice President, Head Product Development, Manufacturing and Supply Chain of the company. Dr. Ray joins the Company from CytoDyn, Inc. where he was Sr. Vice President of Manufacturing and CMC Team Leader. At CytoDyn Dr. Ray developed robust and cost effective manufacturing processes for an antibody therapeutic drug candidate, currently in two Phase 3 clinical studies intended to treat and prevent HIV infection. Dr. Ray led a successful regulatory meetings with the FDA while simultaneously developing strategies for process development, scaleup, validation, commercial manufacturing, and supply chain to support potential commercialization of the CytoDyn HIV therapeutic drug candidate. Prior to CytoDyn, Dr. Ray spent 15 years at Progenics Pharmaceuticals, Inc. a radiopharmaceutical therapeutic and diagnostic company, most recently as Senior Vice President, Manufacturing. At Progenics, Dr. Ray led the development of scalable manufacturing processes and achieved orderofmagnitude cost reduction through improved productivity and scale. In addition, Dr. Ray built process and product development teams for Progenics small molecule, biologics, and radiopharmaceuticals that developed innovative processes for various phases of clinical development and commercial manufacturing. Dr. Ray supported inhouse cGMP biologics manufacturing for Phase 13 clinical development and managed relationships with Contract Development and manufacturing Organizations on a global basis. Dr. Ray also worked at HoffmanLa Roche with a focus on biopharmaceuticals and Verax Corporationrationration in roles of increasing responsibility
Age: 62 President Since 2017
Ray has a Ph.D. in Biochemical Engineering and an M.S. in Chemical and Biochemical Engineering from Rutgers University and a B.S. in Chemical Engineering from Jadavpur University.